

<p>(3) International Patent Classification⁶ : C07C 311/13, 311/24, 311/06, 311/10, C07K 5/062, 5/072, C07D 217/24, A61K 31/18</p>	<p>A1</p>	<p>(11) International Publication Number: (43) International Publication Date: 23 April 1998 (23.04.98)</p>	<p>WO 98/16505</p>
<p>(21) International Application Number: PCT/US97/18396 (22) International Filing Date: 9 October 1997 (09.10.97) (30) Priority Data: 60/028,313 11 October 1996 (11.10.96) US (71) Applicant (for all designated States except US): WARNER-LAMBERT COMPANY [-/US]; 201 Ta- bor Road, Morris Plains, NJ 07950 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): ALBRECHT, Hans, P. [DE/DE]; Am Wetzelsberg 59, D-69517 Gornxheimelnd (DE), ALLEN, Hamish, John [GB/US]; 47 Eastern Point Drive, Shrewsbury, MA 01545 (US); BRADY, Kenneth, Dale [US/US]; 32 Ivenia Road, Worcester, MA 01666 (US); HARTER, William, Glen [US/US]; 3750 Shagbark, Chelsea, MI 48118 (US); KOSTLAN, Catherine, Rose [US/US]; 9876 Moon Road, Saline, MI 48176 (US); ROTH, Bruce, David [US/US]; 49255 Hunt Club Court, Plymouth, MI 48170 (US); WALKER, Nigel [GB/DE]; Frauenpfad 20, D-69221 Dossenheim (DE).</p>		<p>(74) Agents: RYAN, M., Andrea; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 (US) et al. (81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p>	
<p>(54) Title: SULFONAMIDE INTERLEUKIN-1β CONVERTING ENZYME INHIBITORS</p>		<p>Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>	
<div style="text-align: center;"> <p style="text-align: right;">(I)</p> </div>			
<p>(57) Abstract</p> <p>The present invention relates to compounds that are inhibitors of interleukin-1β converting enzyme that have the Formula (I). This invention also relates to a method of treatment of stroke, reperfusion injury, Alzheimer's disease, shigellosis, inflammatory diseases, and septic shock and to a pharmaceutically acceptable composition that contains a compound that is an inhibitor of interleukin-1β converting enzyme.</p>			